Opus Genetics (IRD) Common Equity (2010 - 2026)
Opus Genetics (IRD) posted quarterly Common Equity of -$45.8 million for Q1 2026, down 1003.53% year-over-year from $5.1 million in Q1 2025, and down 398.64% quarter-over-quarter from $15.3 million in Q4 2025.
Opus Genetics (IRD) Common Equity (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Common Equity for 17 consecutive years, with -$45.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 1003.53% year-over-year to -$45.8 million; the TTM figure through Mar 2026 stood at -$45.8 million (down 1003.53% YoY), while the FY2025 annual figure was $15.3 million, up 128.26% from the prior year.
- Common Equity retreated to -$45.8 million in Q1 2026 per IRD's latest filing, from $15.3 million in the prior quarter.
- Across five years, Common Equity topped out at $50.3 million in Q3 2023 and bottomed at -$45.8 million in Q1 2026.
- Historically, Common Equity has averaged $23.2 million across 5 years, with a median of $17.5 million in 2025.
- Annual changes were most pronounced in 2023 — Common Equity surged 323.36% — and 2026, when it plunged 1003.53%.
- Opus Genetics' Common Equity stood at $46.2 million in 2022, then climbed by 7.93% to $49.9 million in 2023, then sank by 86.53% to $6.7 million in 2024, then jumped by 128.26% to $15.3 million in 2025, then tumbled by 398.64% to -$45.8 million in 2026.
- Business Quant data shows IRD's Common Equity at -$45.8 million in Q1 2026, $15.3 million in Q4 2025, and $6.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | -12.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.99 Mn |
| Mar 31, 2026 | -45.84 Mn |
| Dec 31, 2025 | 15.35 Mn |
| Sep 30, 2025 | 5.97 Mn |
| Jun 30, 2025 | 17.47 Mn |
| Mar 31, 2025 | 5.07 Mn |
| Dec 31, 2024 | 6.72 Mn |
| Sep 30, 2024 | 34.30 Mn |
| Jun 30, 2024 | 40.64 Mn |
| Mar 31, 2024 | 46.06 Mn |
| Dec 31, 2023 | 49.91 Mn |
| Sep 30, 2023 | 50.28 Mn |
| Jun 30, 2023 | 37.70 Mn |
| Mar 31, 2023 | 41.25 Mn |
| Dec 31, 2022 | 46.24 Mn |
| Sep 30, 2022 | 11.88 Mn |
| Jun 30, 2022 | 14.60 Mn |
| Mar 31, 2022 | 17.27 Mn |
| Dec 31, 2021 | 22.22 Mn |
| Sep 30, 2021 | 20.57 Mn |